Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 11 Issue 2, May 2017

Volume 11 Issue 2

Medtech Dealmakers

• Medtech dealmaking and financing trends

• A year in diagnostic deals

Cover image: Blue hexagon abstract medical background. MiljaPhoto, Thinkstock.

Medtech dealmaking and financing trends

    Feature

  • News Feature |

    Although the volume and value of merger and acquisition (M&A) deals in the medtech industry both increased in 2016 compared with 2015, M&A activity declined during the year, reflecting the challenges that the industry faces.

    • Amanda Micklus
    • Maureen Riordan
  • Profiles

  • Advertisement Feature |

    Nanowear Inc. has developed next-generation nanosensors for applications in health care and beyond. Building on its first US Food and Drug Administration (FDA) 510(k) clearance for an undergarment that captures multichannel electrocardiograms, Nanowear is now developing a garment to monitor congestive heart failure.

    • Nanowear, Inc.
  • Advertisement Feature |

    Alcon, in partnership with TrueVision 3D Surgical, has launched NGENUITY 3D, a complete digital solution for vitreoretinal surgery that uses an ultra-fast high-definition digital camera to provide an unparalleled three-dimensional view of the retina. The system is designed to improve the visualization of anatomy and pathology, reduce light exposure to the eye, and improve surgeon ergonomics.

    • Alcon Laboratories
  • Advertisement Feature |

    Bioelectronic medicine is on the cusp of becoming a new way to treat disease. The field’s potential to provide new treatment approaches using electric pulses to activate mechanisms in the body has attracted investments from companies including GlaxoSmithKline (GSK) and Google.

A year in diagnostic deals

    Feature

  • News Feature |

    Diagnostics for applications in oncology—particularly immuno-oncology—continued to be the most common focus of dealmaking in the past 12 months, while deals related to Alzheimer’s disease and infectious disease threats such as Zika virus infection were also prominent.

    • Biopharma Dealmakers
  • Profiles

  • Advertisement Feature |

    Osiris Therapeutics, a regenerative medicine company with products for wound care, orthopedics and sports medicine, has developed Prestige Lyotechnology, a proprietary method to preserve living cells and tissues at ambient temperature.

    • Osiris Therapeutics, Inc.
  • Advertisement Feature |

    BioMedica Diagnostics focuses on excellence in the thrombosis and hemostasis market, and takes a truly collaborative approach when sharing its expertise with international partners to enable them to achieve their objectives.

    • BioMedica Diagnostics Inc.
  • Advertisement Feature |

    Clarity Pharmaceuticals leverages a powerful imaging technique called positron emission tomography (PET), and the perfect pairing of copper isotopes, to develop next-generation radiopharmaceuticals for diagnosing and treating cancer and other life-threatening diseases. This approach allows development of innovative ‘theranostic’ products.

    • Clarity Pharmaceuticals
  • Advertisement Feature |

    Established in 1997 in Sydney, Australia, Five Corners is a privately owned clinical research organization (CRO) that provides contract services to manufacturers and distributors of medical technologies that wish to conduct clinical research in Australia and New Zealand.

    • Five Corners Pty Ltd
  • Advertisement Feature |

    Tumor-treating fields (TTFields) use electric fields tuned to specific frequencies to disrupt the division of solid tumor cancer cells. Novocure has launched Optune, its first TTFields delivery system, for the treatment of glioblastoma multiforme and potentially other solid tumor indications.

    • Novocure, Inc.

Search

Quick links